Vera Therapeutics Inc.
VERA | NASDAQ
$36.35
+$2.10 (+6.13%)
Sep 22, 2026, 2:18 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | -846K | n/a | 251K |
Gross Profit | n/a | n/a | n/a | 846K | n/a | -251K |
Operating Income | -315.47M | -167.17M | -102.01M | -90.9M | -34.4M | -48.06M |
Interest Income | 24.48M | 20.71M | 7.98M | 1.75M | 15K | 8K |
Pretax Income | -299.61M | -152.15M | -95.99M | -89.06M | -32.61M | -53.41M |
Net Income | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M | -53.41M |
Selling & General & Admin | 100.22M | 41M | 23.79M | 21.91M | 11.92M | 3.89M |
Research & Development | 215.26M | 126.17M | 78.23M | 69.84M | 22.48M | 43.92M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 315.47M | 167.17M | 102.01M | 91.75M | 34.4M | 47.81M |
Interest Expense | 7.53M | 7.63M | 3.79M | 992K | 20K | 166K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 315.47M | 167.17M | 102.01M | 90.9M | 34.4M | 48.06M |
Income Tax Expense | 1K | 1K | 1K | 1K | 1K | 1K |
Shares Outstanding (Basic) | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M | 3.71M |
Shares Outstanding (Diluted) | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M | 3.71M |
EPS (Basic) | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -14.40 |
EPS (Diluted) | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -14.40 |
EBITDA | -291.62M | -144.42M | -92.18M | -88.91M | -32.41M | -53M |
EBIT | -292.08M | -144.52M | -92.2M | -88.06M | -32.59M | -53.25M |
Depreciation & Amortization | 468K | 105K | 21K | -846K | 176K | 251K |
Add to Watchlist
Select watchlists to add or remove VERA